Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2023
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 January 2023
Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC